Recent Communication with the FDA and CHOP
If you have kept up with our previous articles on MiraLAX safety for pediatric users, or follow the issue in general, you may have noted the ongoing delay in the Children’s Hospital of Philadelphia (CHOP) PEG 3350 study and the lack of information from both CHOP and the FDA on the matter. Refer to our earlier article, “Efforts to Advance MiraLAX Studies and Innovations to Inform the Population”, to grab some details of the study….
FAERS and OpenFDA Inconsistencies
It has come to our attention that running MiraLAX and polyethylene glycol (PEG) 3350 on the FDA Adverse Event Reporting System (FAERS) and OpenFDA gives very different results. FAERS shows the total cases for MiraLAX at 24,413 and PEG 3350 at 26,924. On the other hand, OpenFDA shows the total reports in its database for MiraLAX at 43,340 and PEG 3350 at 64,125….
We mentioned in our February 2019 article, “Efforts to Advance MiraLAX Studies and Innovations to Inform the Population” that there was word of an investigative podcast being created on the MiraLAX issue. The podcast, called “Poisoned”, is now published and aims to be a voice for those affected by the issue and provide expert insight for those who want to know more about it. You can visit the podcast’s website to listen to episodes, view social media, and contact the producers….[Read full article at original source]
Written by: Laura Beasley, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.